Abiomed Receives Close-Out Letter From Food and Drug Administration

Wed Feb 20, 2013 4:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130220:nGNXUXFCGa

DANVERS, Mass., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc
http://www.globenewswire.com/newsroom/ctr?d=10022461&l=1&a=Abiomed%2C%20Inc&u=http%3A%2F%2Fwww.abiomed.com%2F
. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced
that on February 19, 2013, Abiomed received a close-out letter from the Food and Drug
Administration, Office of Compliance with respect to its previous FDA warning letter dated June
10, 2011.

The close-out letter states that the FDA Office of Compliance has completed its evaluation of the
corrective actions taken by Abiomed in response to the previously disclosed FDA warning letter and
that the concerns cited in that letter appear to have been addressed.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that
provide circulatory support. Our products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For additional information please visit:
www.abiomed.com
http://www.globenewswire.com/newsroom/ctr?d=10022461&l=4&a=www.abiomed.com&u=http%3A%2F%2Fwww.abiomed.com%2F
.

The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564
http://www.globenewswire.com/newsroom/ctr?d=10022461&l=5&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D13564


FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of
Abiomed's existing and new products, the Company's progress toward commercial growth, and future
opportunities and expected regulatory approvals. The Company's actual results may differ
materially from those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and related regulatory
approvals, including the potential for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition, technological change,
government regulation, litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings with the Securities
and Exchange Commission, including the most recently filed Annual Report on Form 10-K and
quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release. The Company
undertakes no obligation to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances that occur after the date of this
release or to reflect the occurrence of unanticipated events.

CONTACT: For further information please contact:
         
         Susie Lisa, CFA
         Senior Director, Investor Relations and Corporate Development
         978-646-1590
         slisa@abiomed.com
         
         Aimee Maillett
         Corporate Communications Manager
         978-646-1553
         ir@abiomed.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.